(Reuters) -Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million. The company's shares opened at $16.12 apiece, ...
Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...
Rivers are some of the most fascinating natural wonders on Earth. They provide water, support wildlife, and are also the ...
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Read more ...
Quebecor Inc. est une société de communication intégrée. Ses secteurs d'activité sont les télécommunications, les médias et les sports et divertissements. Le secteur Télécommunications ...
IPO content provided by Renaissance Capital LLC, manager of the IPO-focused ETFs (tickers: IPO, IPOs).
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback